AzTrials
AzTrials

Mouth UlcerDERMAL-LRNCT06969495

Pilot Clinical Study Testing Tiger Milk Mushroom Gel (Lignosus Rhinocerus TM02®) for Treating Mouth Ulcers

A study testing xLr oral gel and Kanolone in people with Mouth Ulcer, run by Mahsa University at 1 site in Malaysia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a pilot clinical trial study to investigate the wound healing capability of a TM02® water extract formulation in patient with minor oral ulcers (2 - 5 mm in size). The sclerotium of L. Read more about this study

Who is it for?
Ages 20 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Mouth Ulcer
What is being tested?
xLr oral gel and Kanolone
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
21 participants
Where
1 siteMalaysia
Study dates
1 Feb 2023to 23 Feb 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Male and female participants aged between 20 and 50 years
  • No history of systemic diseases such as leukemia, hemophilia, uncontrolled diabetes mellitus, or serious cardiac conditions
  • Presence of minor oral aphthous ulcers ranging from 2 to 5 mm in size
  • No use of medications, including topical steroids or mouthwashes, for at least 3 months prior to the study
  • Willingness to provide written informed consent and adhere to the study protocol.

Who cannot join

  • Pregnant or lactating women; Known allergies to any components of the study formulations
  • Any condition that, in the opinion of the investigator, may interfere with the study objectives or participant safety.

Trial locations and contacts

1 site in 1 country.

Malaysia1 site
  • MAHSA University Dental Clinic

    Jenjarum, Selangor, 42610

Other trials in Malaysia

About this study

Official title: A Clinical Investigation Into the Dermal Application of L. Rhinocerus TM02(r) Water Extract for Mouth Ulceration

This is a pilot clinical trial study to investigate the wound healing capability of a TM02® water extract formulation in patient with minor oral ulcers (2 - 5 mm in size). The sclerotium of L. rhinocerus is traditionally used as a health tonic or treatment regime for asthma, bronchitis, various cancer ailments as well as discomforts caused by fright, fever, cough, vomiting, and injury. Further on to that, this mushroom has also been traditionally used by the local Malay and Chinese communities to treat wounds, although it is yet to be scientifically validated. Its sclerotia are being consumed in the form of decoction, in a betel quid, and other preparation method where the sclerotium is pounded with raw rice, infused, and subsequently taken as a drink. There is also a practice of biting/chewing of the sclerotium by local indigenous communities during their journeys in the wild.

Read the detailed description

Project overview Lignosus rhinocerus, commonly known as tiger milk mushroom (TMM), is a medicinal fungus native to Southeast Asia. Traditionally, it has been utilized for various health conditions, including wound healing. Recent studies have highlighted its anti-inflammatory, antimicrobial, and immunomodulatory properties, particularly in its cultivated form, TM02® .

Aphthous ulcers, or recurrent aphthous stomatitis (RAS), are common, painful lesions of the oral mucosa affecting a significant portion of the adult population. Current treatments primarily involve topical corticosteroids, which may have side effects with prolonged use. Given the traditional use of L. rhinocerus in wound care, this study aims to evaluate the efficacy of TM02® gel in treating minor oral aphthous ulcers.

Hypothesis and general objective Hypothesis: L. rhinocerus cultivar TM02® gel accelerates the healing process of minor oral aphthous ulcers compared to standard treatments.

Primary Objective: To assess the efficacy of L. rhinocerus TM02® gel in promoting the healing of minor oral aphthous ulcers.

Methodology Mushroom Material and Gel Formulation Lignosus rhinocerus TM02® freeze-dried sclerotia powder (TM02®) was obtained from LiGNO Biotech Sdn. Bhd. (Selangor, Malaysia). This commercially available product is officially registered under the Protection of New Plant Varieties Act (NPVA), Malaysia (Registration No.: PVBT010/11). The authenticity of TM02® was confirmed via polymerase chain reaction (PCR) amplification and sequencing of the internal transcribed spacer (ITS) region. To extract its bioactive compounds, the sclerotia powder underwent cold water extraction at a 1:20 ratio of powder to distilled water, followed by centrifugation and freeze-drying. The resulting extract, referred to as xLr®, was then formulated into an oral gel by incorporating it with xanthan gum as a thickening agent and 0.5% sodium benzoate as a preservative. The final gel formulation (containing 25% xLr®) was stored at room temperature until further use.

Study Design and Ethical Approval A double-blinded, randomised clinical trial was conducted with approval from the Research Management Centre, MAHSA University (Ethics No.: RMC/EC45/2022). Prior to enrolment, all participants received a patient information sheet detailing the study objectives, procedures, potential risks, and benefits. Informed consent was obtained from each participant before proceeding. Systemically healthy patients presenting with minor, isolated aphthous ulcers were recruited, while individuals taking medication, using mouthwash, or consuming herbal products were excluded. A third party managed the randomisation process to ensure impartiality, and both investigators and participants remained blinded to the assigned treatments. For participants with language barriers, a student translator assisted in explaining the study details and consent process to ensure clear communication. All study procedures were conducted in accordance with ethical guidelines and clinical protocols.

Treatment Protocol A total of 21 patients (8 males, 13 females), aged 20-50 years, were randomly allocated into three groups. The control group received the base formulation without xLr®, the test group received the xLr® oral gel, and the standard treatment group was given Kanolone Oral Base Paste (Triamcinolone acetonide 0.1%). Patients were instructed to apply a thin layer of the assigned gel to the ulcer using a dry cotton bud three times daily for seven days, ensuring no eating or drinking for at least 30 minutes post-application.

Clinical Evaluations Pain levels were recorded daily for seven days using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst pain). Ulcer size was measured on Days 1, 3, 5, and 7 using a transparent grid overlay. Each square on the grid represented a surface area of 4 mm². The total ulcer area (mm²) was determined by counting the number of squares within the ulcer's outline, providing an objective assessment of wound size over time. Wound epithelialisation was assessed on Days 3, 5, and 7 by applying a 3% hydrogen peroxide (H₂O₂) solution to the ulcer site. Bubble formation indicated incomplete epithelialisation, whereas the absence of bubbles signified complete epithelialisation, providing a clear and reliable measure of the healing process over time. For cases where epithelialisation required more than seven days-exceeding the study's observation period-it was assigned a value of 8 for analytical consistency.

Study Site The trial was conducted at MAHSA University's clinical facilities, specifically within the Faculty of Dentistry.

Conditions
Mouth Ulcer
Being tested
xLr oral gel, Placebo, Kanolone
Keywords
Tiger Milk Mushroom, Mouth ulcers, Wound healing, Natural remedies
Medical subject headings
Oral Ulcer

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • xLr oral gelOther

    Also called TM02 gel

    25% of Cold water extract of Tiger milk mushroom sclerotial powder in a gel form containing xanthan gum as a thickening agent and 0.5% sodium benzoate as a preservative.

  • PlaceboOther

    Also called Vehicle ctrl

    oral gel base formulation without the Lignosus rhinocerus extract

  • KanoloneDrug

    Also called Positive ctrl

    Kanolone Oral Base Paste (Triamcinolone acetonide 0.1%)

Study groups in NCT06969495
Study groupRoleWhat they receive
Base formulationPlacebo comparatorParticipants will receive an oral gel base formulation without the Lignosus rhinocerus extract. The placebo gel will be applied to the mouth ulcer three times daily for seven days.
Receives: Other: Placebo
xLr oral gelExperimentalParticipants will receive an oral gel containing 25% Lignosus rhinocerus TM02® cold water extract (xLr®). The gel will be applied to the mouth ulcer three times daily for seven days.
Receives: Other: xLr oral gel
Kanolone Oral Base PasteActive comparatorParticipants will receive Kanolone Oral Base Paste (Triamcinolone acetonide 0.1%), a standard topical corticosteroid treatment for aphthous ulcers. The paste will be applied to the mouth ulcer three times daily for seven days.
Receives: Drug: Kanolone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain Assessment

    Pain levels were assessed daily over a seven-day period using the Visual Analog Scale (VAS), where 0 represented no pain and 10 indicated the worst possible pain.

    Measured: Daily assessments on Days 1 through 7 during the intervention

  2. Wound Epithelialization

    Wound epithelialisation was evaluated on Days 3, 5, and 7 by applying a 3% hydrogen peroxide (H₂O₂) solution to the ulcer site. The formation of bubbles indicated incomplete epithelialisation, while the absence of bubbles signified complete epithelialisation, offering a reliable and consistent measure of the healing process.

    Measured: Assessments on Days 3, 5, and 7 during the intervention

  3. Ulcer size

    Ulcer size was measured on Days 1, 3, 5, and 7 using a transparent grid overlay. Each square on the grid represented a surface area of 4 mm². The total ulcer area (mm²) was determined by counting the number of squares within the ulcer's outline, providing an objective assessment of wound size over time

    Measured: Days 1, 3, 5, and 7 during the intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 May 2025
  2. Study start1 Feb 2023
  3. Primary completion30 Nov 2023
  4. Study completion23 Feb 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
21 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06969495
Sponsor's protocol ID
RP185_05/22
Acronym
DERMAL-LR
Status last verified
May 2025
First submitted
28 Apr 2025
Last updated
15 May 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing xLr oral gel and Kanolone in people with Mouth Ulcer, run by Mahsa University at 1 site in Malaysia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain Assessment (time frame: Daily assessments on Days 1 through 7 during the intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in